ACTRN12606000064505尚未招募不适用
A Randomised Double Blind Placebo Controlled Trial of Site Specific Clonidine Patches In Treatment of Neuropathic Wound Pain Following Caesarean Section
Tim Short0 个研究点目标入组 60 人开始时间: 2006年2月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- All
入选标准
- •patients who fit the following criteria: The diagnostic criteria of Hayes et al (2002) have been modified for this study. They propose that 5 of 8 features suggestive of neuropathic pain need to be present for the diagnosis to be made. One of these features (history consistent with nerve injury) is considered satisfied in all caesarian section patients in view of their surgical history. Another, (associated autonomic features) is neither sought nor seen frequently in caesarian section patients. We are therefore left with 4 of 6 features as follows:1.Pain in the absence of evidence of ongoing tissue damage2.Character of pain from any of: burning, stabbing, pulsing.3.Paroxysmal or spontaneous pain4.Presence of any of: allodynia, hyperalgesia, hyperpathia5.Pain within an area of sensory deficit6.Associated dysaesthesias
排除标准
- •1.Known previous hypersensitivity to clonidine or clonidine patches2.Current treatment for other neuropathic pain states3.Current treatment with clonidine, tricyclic antidepressants, anti convulsants, or oral sodium channel blockers eg mexiletine.4.Patients who would normally require an interpreter for informed consent or to properly interpret pain scoring.5.Patients with a vertical surgical incision.6.Patients with severe bradyarrythmia due to sick sinus syndrome or 2nd or 3rd degree AV block.7.Discharge or transfer anticipated within following 24 hours8.Refusal of informed consent.9.Patients currently on other antihypertensive agents.10.Patients in whom an ilioinguinal nerve block has been performed.
研究者
相似试验
进行中（未招募）
不适用
A Randomized Double-Blind Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25 mg Twice Weekly in Subjects with Moderate to Severe Persistent AsthmaModerate to severe asthmaticsEUCTR2004-003778-27-FIWyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development120
进行中（未招募）
1 期
A Randomized Double-Blind Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25 mg Twice Weekly in Subjects with Moderate to Severe Persistent AsthmaModerate to severe asthmaticsEUCTR2004-003778-27-GBWyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development120
进行中（未招募）
不适用
A Randomized Double-Blind Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25 mg Twice Weekly in Subjects with Moderate to Severe Persistent AsthmaModerate to severe asthmaticsEUCTR2004-003778-27-SEWyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development120
已完成
不适用
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease-C34 Malignant neoplasm of bronchus and lungMalignant neoplasm of bronchus and lungC34PER-147-09PFIZER S.A., National Cancer Institute of Canada - Clinical Trials Group (NCIC CTG),
尚未招募
3 期
A study of the effect of Alpha lipoic acid in addition to the usual treatment drug in schizophrenia patientsCTRI/2023/12/060745Dr Ramya R